Pipobroman - CAS 54-91-1

Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET) . Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.

DNA/RNA Synthesis, DNA Alkylator/Crosslinker

Cell Cycle/Checkpoint, DNA Damage/DNA Repair

54-91-1

0.9708

C10H16Br2N2O2

356.05

BrCCC(=O)N1CCN(CC1)C(=O)CCBr

-20°C

Ice Packs

Small Compound